

Alejandrina Malacara Villaseñor

Medical Affairs Head

Alejandrina was born in León, Guanajuato (Mexico) on January 20th, 1971.

She earned her medical degree from the University of Guanajuato in **1995**. Furthering her expertise, she specialized in Internal Medicine and Nephrology at the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ), completing her residency in **2003**. Alejandrina pursued additional education, obtaining a Diploma in Pharmaceutical Marketing at ITESM and completing various professional courses in bioequivalence and vaccinology.

Alejandrina's career spans over **18 years** in Medical Affairs within multinational pharmaceutical companies. She began as Medical Affairs Manager at Boehringer Ingelheim, where she contributed to the successful launch of the first oral anticoagulant in Mexico. She later transitioned to Bristol-Myers Squibb and she held various leadership positions at Sanofi.

At Sanofi, she served as Country Medical Head for Vaccines, in this role, Alejandrina was responsible for the development and execution of scientific strategies, including the launch of new vaccines and pandemic response efforts, achieving a **95%** vaccination rate. She led and restructured her team to meet key medical and business goals, collaborating with internal and external stakeholders to ensure successful outcomes.

She also held prominent positions at Boehringer Ingelheim and Bristol-Myers Squibb, refining her expertise in medical operations, strategic planning, and team management. Alejandrina is known for building high-performing teams and fostering strong relationships with key scientific experts, helping to elevate her organization's medical and scientific impact.

In **2024**, Alejandrina joined Chiesi Mexico as the Head of Medical Affairs. In this role, she leads national initiatives, driving medical strategies with an emphasis on scientific excellence and integrity. Her focus is on fostering collaboration between medical professionals and research, while aligning with the commercial strategies of pharmaceutical and medical device companies. As a critical intermediary, she provides valuable scientific insights and contributes to strategic decision-making processes.